1 / 40

Pharmaceutical Life Cycle Management (LCM)

CONFIDENTIAL. Pharmaceutical Life Cycle Management (LCM). Client workshop. June 2001. Today´s discussion. Key elements of Life Cycle Management. Thoughts on how to organize for LCM. Key issues. * Footnote Source: Source. Life Cycle Management. Objective.

geer
Download Presentation

Pharmaceutical Life Cycle Management (LCM)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. CONFIDENTIAL Pharmaceutical Life Cycle Management (LCM) Client workshop June 2001

  2. Today´s discussion • Key elements of Life Cycle Management • Thoughts on how to organize for LCM • Key issues * Footnote Source: Source

  3. Life Cycle Management • Objective • Life Cycle Management is largely about building brands over time –by incremental investments in value creating activities to maximize the value of a compound • Mindset • Building a business based on a great product idea/brand – • not just launch an innovation

  4. LCM requires a commercial mindset • Setting ambition level • Shape the product • Shape the market • Shape • the company

  5. Shape the product LCM requires a commercial mindset • Setting ambition level • Early cross functional agreement on vision for the product (target label) • Invest with a venture capitalist mindset • Deliver against timeline • Focus on what is important • Continuously enhance competitive differentiation • Clinical development entirely focused on value creation (e.g., most important indications)

  6. Shape the market LCM requires a commercial mindset • Setting ambition level • Shape the market early and actively • Clear and consistent messages in communication/PR strategies • Recognize regional differences in key markets • Clear and broad perspective on resources required to shape the market • Ensure tight link between R&D strategy and market strategy

  7. Shape • the company LCM requires a commercial mindset • Setting ambition level • Have a consistent and transparent commercialization process • Market leading where it really matters • Strong motivation among employees to bring product to market • Partnership/communications across functions/teams/MCs • Timely training of all relevant employees

  8. LCM requires a commercial mindset • Setting ambition level • Shape • the product • Shape the market • Shape • the company • Early cross functional agreement on vision for the product (target label) • Invest with a venture capitalist mindset • Deliver against timeline • Focus on what is important • Continuously enhance competitive differentiation • Clinical development entirely focused on value creation (e.g., most important indications) • Shape the market early and actively • Clear and consistent messages in communication/PR strategies • Recognize regional differences in key markets • Clear and broad perspective on resources required to shape the market • Ensure tight link between R&D strategy and market strategy • Have a consistent and transparent commercialization process • Market leading where it really matters • Strong motivation among employees to bring product to market • Partnership/communications across functions/teams/MCs • Timely training of all relevant employees

  9. Actions often taken years earlier! The life cycle can be divided into three phases Typical industry curve Potential curve with active LCM • Phase • Launch • Extend • Sustain • Year 0–4 5–10 11+ • Overall ambitions • Gain market share • Establish market • Rapid sales ramp-up • Expand market • Gain market share • Minimize impact of generics • Develop and launch line-extensions

  10. Rapid growth in market share (x% by year 4) • Establish overall market (from y to z billion USD) • Rapid sales ramp up (a% of year 4 sales in year 2) • Align and anchor targets with entire organization • Ambitions • Rapid launch across all markets • Product label/positioning/branding is consistent and differentiated • Competitor moves and strategies assessed and implications taken – in advance • LCM strategy/positioning over time is clearly identified • Shape the product • Establish KOL network and build base for ongoing relationship • Pricing strategy balances need for quick approval/penetration and establishing favorable long-term position • Marketing mix and focus on key influencers to reach ambition • Clinical “share of voice” and publication levels of sufficient magnitude and quality • Shape the market • Competitive investment level across markets (e.g., x per patient) • Transition global team role and composition; • Educate, excite and align local teams and sales force • Create and maintain master planning chart of launch activities • Negotiate possible alliances/co-promotion arrangement to optimize geographical coverage • Shape the company Best practice targets for ”launch” phase

  11. Selecting the right label requires a clear ambition • Example of ambition level staircase • Key input into label • Product name, project name • Product vision • Competitive environment • Main patient and customer groups and their key unmet needs • Pricing strategy • Key claims for launch • Go/no go • Relative value • Route of administration • Dosing regimen • Label indication(s) • Launch date • Key issues • Expand the market • What label is needed to get to the next step? • Class leader • Get “fair share” • Minimally accepted level • No go

  12. Trend towards compressed launch schedules – case example: Pfizer • Number of countries* • Worldwide salesUSD billions • Viagra (98) • Lipitor (97) • Lipitor** • (with WL) • Norvasc (90) • Viagra** • Zoloft (90) • Norvasc • Zoloft • Years after launch • Years after launch * Number in parentheses denotes first launch date worldwide ** Includes forecasts because time horizon extends past 1998 Source: FDA; pink sheets; 10-K; Morgan Stanley analyst report (7/98); McKinsey analysis

  13. Marketing investment becoming more aggressive • Projected • Cumulative US details • Thousands • Cumulative US sales • USD millions • Lipitor • (1997) • Lipitor • Pravachol • (1991) • Pravachol • Years from launch • Years from launch Source: Sales and details from Scott Levin US

  14. Identify key bottlenecks for most attractive consumer/prescriber segments • Evaluate where in the purchase funnel major bottle-necks exist for high-value patients and physicians • Identify which drivers can resolve the bottleneck(s) • How to increase awareness, induce trial, retain patients and physicians, etc.? • 1 • 2 • 4 • 3 • Track results against segment bottlenecks • Develop scorecard to evaluate results from marketing solutions • Focus message and spend on eliminating bottlenecks • Develop marketing solutions and evaluate each based on ability to resolve bottleneck, ease of implementation and cost Dynamic marketing model • Many large pharmaco’s are still in the process of adopting this tool

  15. ILLUSTRATIVE EXAMPLE Example of physician decision funnel • Physician is aware of new drug • Physician considers new drug • Physician differen-tiates new drug from old drug • Physician tries new drug • Physician endorses new drugs for patients with unresolved symptoms • Physician endorses new drug for all old drug users • Bottle-necks • Few, if any, unmet needs • No long-term safety profile • Believes that new drug efficacy is not significantly superior to that of old drug • Lack of samples • Lack of experience with new drug; prefer true and tested drug • New drug is not on many formularies/ physician does not want to deal with MCO callbacks • Physician does not want to switch patient who is stable on old drug • Not all patients respond well to new drug • New drug is not on many formularies • New drug does not have full range of indications

  16. Publication volume is important in differentiating drug products Correlation between drug sales and publications Sales USD millions Cozaar 620 • Diovan (Novartis) launched in 1994 one year after Cozaar (Merck) with a higher efficacy and better tolerated drug; however, Cozaar was able to leverage a 5–32x greater publication volume to beat Diovan 420 220 Diovan 20 1992 93 94 95 96 97 98 Number of citations 1000 750 500 Cozaar 250 Diovan 0 2Q99 1992 93 94 95 96 97 98 Source: Cited reference science database, various marketing/sales database and publications

  17. EXAMPLE Master planning chart Top level milestones • MS1 • MS2 • TG1 • MS4 • TG2 • TG3 • TG4 • MS8 • Process • Global marketing • Target label • Only if issues/LCM* • Disease orientated • Updated disease orientated • Final disease orientated • Initial project specific – staircase • Refined based on market research and trial results – staircase • Final pre-launch • Covers key dimensions • Product development • Global marketing • Product supply • Patents • Etc. • Top level milestones and more detailed activities • Positioning • Reposition if necessary • Broad initial • Updated as CD is elected • Updated based on develop-ment studies and focus groups with KOLs • Final pre-launch based on market research and clinical trials • Branding • Rebranded only in unusual situations • Initial very preliminary • Updated based on market research and focus groups • Final pre-launch based on input from markets and trials * Updated annually

  18. Maximize growth of franchise over time through share and market growth • Ambitions • Deliver studies to evolve product positioning and respond to competitive and market shifts – focus on incremental sales • Evolve the product (e.g., drug delivery methods) and add value-added offerings (e.g., diagnosis support) • Pursue local clinical studies balancing need/demands of local markets with diminishing returns of global positioning • Shape the product • Shape the market • Evolve marketing mix and focus over time • Appropriately focus KOL activities to maintain network and respond to new competitors • Increase the size of the market through investments to broaden usage and enhance diagnosis • Secure optimal geographical coverage by alliances/co-promotion • Shape the company • Develop and retain product teams on global and local level • Ensure sales force incentives drive evolution of existing prescribers and conversion of new prescribers Best practice targets for ”extend” phase

  19. Examples of product extensions • New indication • Further/expanded indications • Patient based innovation • Line extensions • Pharmaco–economic • Safety/tolerability profile

  20. New indication • Identifying diseases/symptom currently poorly/not treated and developing novel products • Proscar (Merck) • Captopril (BMS) • Reo-Pro (Centocor) • Acculane (Roche) • Further/expanded indications • Expanding relevant patient population by redefining diseases of by treating additional diseases (formulation combinations) • Fosamax (Merck) • Mevacor (Merck) • Coreg (BM) • Wellbutrin/Zyban (GW) • Line extensions • Adapting product to avoid/delay generic competition • Voltarol (Geigy) • Amoxil (SB) • Procardia XL (Pfizer) • Safety/tolerability profile • Focusing product development/marketing on addressing safely issues with incumbent therapies • Istin/Norvasc (Pfizer) • Cardizem (HMR) • Zantac (GW) • Pharmacoeconomic • Defining p-economic profile by e.g., redefining clinical end points for competitive advantage • Rocephin (Roche) • IPA/GUSTO (Genentech) • Dipravan (AstraZeneca) • Patient-based • Innovating around the specific need of patients • Easi-Breathe (3M) • Novopen (Novo Nordisk) • Menorest (RPR) Examples of product extensions • Ways to create product extension • Examples • Description

  21. Capturing benefits of continued research • 25-40% of sales of top selling drugs in UK/USA are for indications discovered only after the drugs were launched Source: UK office of Health Economics/Market letter June 13, 2001

  22. DISGUISED EXAMPLE Impact of new indications • Experience shows • Substantial spillover effects from being first company to launch indication • First mover can get up to 10% more market share even where off-label exists • The follower – running the same indications – usually is not able to improve his market position • Example of possible indications for SSRIs • Major depression • Prevention of relapse of depression • Premenstrual dysphoric disorder • Anxiety – general and panic attacks • Obsessive compulsive disorders • Eating disorders – anorexia and bulimia • Substance abuse • Social phobia • Where can company gain share by pioneering indications? • Where can company leverage class effect?

  23. Sustained results with proactive Life Cycle Management – example Voltaren • "Patent life" extended 10 years after expiry through proactive product re-launches • USD 1 billion global sales in 1997 • Global market share • Percent Sales in Germany DEM Millions • 160 Gel • 120 Sustained release • 80 Suppository • 40 Plain • 0 • 1993 • 94 • 95 • 96 • 97 • 1982 • 83 • 84 • 85 • 86 • 87 • 88 • 89 • 90 • 91 • 92 • 93 Patent expiry Source: IMS

  24. Sponsored • Supported Increasing challenge to maintain KOL network demands focus • Characterization • “Thought leaders” • Provide critical data • Prescribers • Marketing measures • Scientific events initiated by company • Involvement in sales force training • OPL • “Influencers” • Heavily involved in teaching • “Followers” • Command vast majority of prescriptions • Very heterogeneous and volatile limited understanding • Special company events to leverage OPLs, e.g., “Semi-Annual update” for heavy prescribers • Sales force visits • High prescribers • “Laggards” • Lag behind new therapy developments • Information using marketing measures other than sales force contact • Low prescribers

  25. Retaining and motivating top talent over years requires more than money • Values and culture • Well managed product • Company has exciting challenges • Strong performance • Freedom and autonomy • Job has exciting challenges • Career advancement and growth • Great tasks • Great • product • Compensation • Differentiated compensation • High total compensation

  26. Ambitions • Maintain market share and profit levels as long as possible • Shape the product • Identify and invest in levers to extend life cycle • Shape the market • Review pricing as a key lever to measure product value • Extend sales and marketing activity • Shape the company • Ramp up excitement and on local teams to extend the franchise • Shift composition of global team to meet demands of sustaining lifecycle • Address internal barriers to sustaining franchise Best practice targets for ”sustain” phase

  27. Increase sales spending • Improve sales effectiveness • Increase market spending • Improve marketing effectiveness • Attain additional indications • Maximize remaining sales • Migrate to new proprietary products • Exclusive product enhancements/extensions • ”New” versions of product • Parse the market • Create product • extensions • Litigate • Manage regulatory affairs • Take competitive actions • Defend sales • exclusivity • Produce own generic • Partner with generics • Maximize contribution • Migrate to OTC • Compete in generic market • License • Trade • Sell • Transfer ownership 5 key competitive levers to maximize late life cycle NPV • Key levers • Possible actions

  28. Recognition of the threat and opportunity • New product bias • Resource capacity constraints Internal barriers to address lifecycle extensions • Possible response • Determine which generic competitors are likely to enter • Study case examples • Use scenario modeling to quantify impact and assess potential opportunity • Establish more sophisticated risk/reward measures • Focus on total product opportunity rather than annual budgeting for in-line products • LCM revenues important to sustaining performance through ”droughts” • Outsource the LCM work to conserve in-house resources, e.g., transferring ownership

  29. Deal • structure, negotiation and alliance manage-ment • Regulatory affairs • Regulatory affairs • Sales/ marketing • Litigation strategy and tactics • Clinical development • Clinical development Non-traditional skills needed in late Life Cycle Management • Traditional • Focus: This year’s profit plan • Required • Focus: NPV of asset • Licensing and acquisitioning/ partnering • Sales effectiveness • Product team • Product team

  30. Today´s discussion • Key elements of Life Cycle Management • Thoughts on how to organize for LCM • Key issues

  31. Design principles • Drive life cycle management around the major planning events (early on milestones and later in annual planning cycle) • Document life cycle management thinking in a simple document that potentially is broader than the business plan document • Create clear roles and responsibilities between global and markets

  32. Focus areas and early recommendations • Make LCM-plan an integral part of tollgate decisions • Make LCM planning part of annual portfolio management process • Clarify decision-making around LCM • Define roles and responsibilities • Define who has what responsibilities • Upgrade the LCM-plan to a real annual strategy document for post launch • Define the company LCM-plan (aligned with markets) • Define the company life cycle plan • Clarify leadership – commercial versus technical • Create a standing/recurring LCM sub-team including key markets • Organize for creation and management of the LCM-plan • Define the role in annual planning • Define the company minimum standard • Link budgets to LCM planning • Make LCM a priority in annual planning

  33. ILLUSTRATIVE Life cycle thinking should be part of the early development tollgate decisions • Pre-CD • CD nomination • Proof of concept • Approval to launch • Choice of first indication • Target label assessment • Preliminary target • Target label evolution over time • Patent/IP strategy • Choice of CD and backup • Rough life cycle vision • Future development activities • Evolution of positioning • Updated target label assessment • Staircase • Development project plan for proposed scenario • Scope • Scale • Investment for speed • Updated LCM plan • Agreed vision with markets • Future development initiatives • Evolution of positioning • Future marketing initiatives • Updated development project plan for proposed scenario • Ensure supply • Updated target label assessment • Final “launch” target label • Updated LCM plan

  34. EXAMPLE A good LCM plan considers a broad range of strategic initiatives • Market penetration programs • Marketing and sales • Global positioning and coordination programs • New marketing/sales approaches • New claims/ indications What is required to reach vision/ objectives? • Clinical development • Line extensions • Repositioning of other classes • Production and logistics improvement program • Other • Renegotiate alliance agreement

  35. ILLUSTRATIVE Create quality standard overall and within the LCM plan • Examples • Decisions should be based on a deeper level of insight into overall market situation than what resides in any single market • Avoid doing “a little of everything” • Avoid mismatch between global and local ambition. Be clear on overall strategic direction • Each plan should increase the future value of product based on defining essential activities for product growth • Ensure that initiatives focus on both development and marketing levers across time • Use innovative tools and framework to push thinking (e.g., “war games”, strategic staircases etc)

  36. EXAMPLE • 1. Executive summary • Outline plan for the brand • Explain the overall LCM strategy and performance objectives • Describe the 3–5 main issues that may significantly affect the product success • Lay out actions to resolve issues • Does the executive summary clearly and concisely articulate how the product will win in the market place and overcome any significant challenges? • 3. Situation analysis • Market development • Customer needs • Product profile • Product market performance • SWOT analysis • Have forecasts (best–worst) been assessed and validated • Are all assumptions stated clearly? • Have deviations from previous forecast been assessed and explained? • Does the competitive analysis give us: • Understanding of how the players in the market have acted and positioned themselves • Opportunities for our product? • Anticipated competitor actions on reactions in our LCM strategy so that we can act proactively? Life cycle plan – annual portfolio review post launch • Chapter • Content • Quality guideline • 2. Decision required • Explain what management is asked to decide on • Does the section clearly lay out the needed resources for the recommended option as well as the two–three alternatives?

  37. EXAMPLE Life cycle plan – annual portfolio review post launch – cont. • 4. Long term life cycle vision • 5. Objectives • 6. Strategy (short-, mid- and long-term) • 7. Global product/brand team and satellite team composition • 8. Critical success factors • 9. Action plan • 10. Financials • 11. IPP

  38. FOR DISCUSSION Life cycle management team – example • Critical that thought leadership comes directly from global brand/product responsible • Brand director will often provide day-to-day team leadership • Requires dedicated standing/recurring satellite team, often with direct market participation (1–2 people) • The role of the sub-team is to drive fact gathering, perform analysis, synthesize conclusions and draft/build buy-in for LCM strategy • Quality planning for a major brand takes 3–4 months and 3–5 fulltime people

  39. Today´s discussion • Key elements of Life Cycle Management • Thoughts on how to organize for LCM • Key issues

  40. Key issues • Are we creating enough value through Life Cycle Management today? • How important is LCM to our growth over the coming years? • Do we have a simple manual laying out the “COMPANY-way” of doing LCM? • Is LCM a sufficiently large part of our annual planning process? • What are the most critical gap areas? • Is the way we organize for LCM sufficiently clear, e.g., are teams composed (global/local) based on recognition of commercial challenge over time?

More Related